Table 2.

Coagulation and fibrinolysis in patients with COVID-19

	Severe/non-severe (n = 173/926)	ARDS/non-ARDS (n = 53/56)	ICU/non-ICU (n = 13/28)	Severe/non-severe Pneumonia (n = 38/72)	Non-survivor/survivor (n = 54/137)	Non-survivor/survivor (n = 21/162)	Non-survivor/survivor (n = 32/20)	Non-survivor (n = 82)
D-dimer, >1 mg/L	59.6/43.2 (≥0.5 mg/L)	940/370c	2.4/0.5b	1.11/0.37c	5.2/0.6d	2.12/0.61c, 100/		97.5–100 (>0.55 mg/L)
FDP, mg/L						7.6/4.0c
Fibrinogen, g/L		3.4/2.9c				5.16/4.51, 28.6 (<1 g/L)		—
Platelets, <100 × 109/L	57.7/31.6 (<150,000/mm3)		8/4	144.5/179.5c (109/L)	20%/1%d	57.1/	191/164	63.2
Prothrombin time, ≥16 s			12.2/10.7a		13/3a	15.5/13.6c		100 (>12.1)
Antithrombin activity						84/91	12.9/10.9
APTT, s			26.2/27.7			44.8/41.2
ISTH DIC criteria						71.4/-
Reference no.	24	45	31	85	101	79	95	97

APTT, activated partial thromboplastin time; ARDS, acute respiratory distress syndrome; DIC, disseminated intravascular coagulation; FDP, fibrin degradation products; ICU, intensive care unit; ISTH, International Society on Thrombosis and Hemostasis.

^aP < 0.05,

^bP < 0.01,

^cP < 0.001,

^dP < 0.0001.